OOIR: Observatory of International Research

Papers

(The H4-Index of JAMA Dermatology is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040	431
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis	283
Psoriasis Prevalence in Adults in the United States	224
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis	203
Lack of Transparency and Potential Bias in Artificial Intelligence Data Sets and Algorithms	150
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis	112
Prevalence of Hidradenitis Suppurativa	108
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine	107
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa	105
Systemic Immunomodulatory Treatments for Atopic Dermatitis	95
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis	93
Checklist for Evaluation of Image-Based Artificial Intelligence Reports in Dermatology	88
Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults	83
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic	81
UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome	76
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy	75
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis	74
Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride	67
UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color	67
Association of Wildfire Air Pollution and Health Care Use for Atopic Dermatitis and Itch	67
Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines	65
Sirolimus (Rapamycin) for Slow-Flow Malformations in Children	63
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders	63
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab	61
Dermatologist Perceptions of Teledermatology Implementation and Future Use After COVID-19	61

Mucocutaneous Manifestations of Multisystem Inflammatory Syndrome in Children During the COVID-19 Pandemic	58
Insurance Acceptance, Appointment Wait Time, and Dermatologist Access Across Practice Types in the US	57
Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis	54
Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis	53
Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare	52
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis	51
Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis	50
Rates of Vascular Occlusion Associated With Using Needles vs Cannulas for Filler Injection	50
Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures	50
Prevalence of Vitiligo Among Adults in the United States	48
Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma	47
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis	46
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma	44
Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome	43
Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome	43
Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US	42
Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients	42